Cytochrome P450 inhibitory potential and RP-HPLC standardization of trikatu鈥擜 Rasayana from Indian Ayurveda

详细信息    查看全文

• 作者：Ranjit K. Harwansh^a ; Kakali Mukherjee^a ; Santanu Bhadra^a ; Amit Kar^a ; Shiv Bahadur^a ; Achintya Mitra^b ; Pulok K. Mukherjee^a ; ^{naturalproductm@gmail.com" class="auth_mail}
• 关键词：Ayurveda ; Rasayana ; Trikatu ; Herb&ndash ; drug interaction ; Cytochrome P450 ; Spices
• 刊名：Journal of Ethnopharmacology
• 出版年：14 May 2014
• 年：2014
• 卷：153
• 期：3
• 页码：674-681
• 全文大小：1011 K

文摘

Trikatu is a very well known ‘Rasayana’ in Ayurveda and widely used as a polyherbal ayurvedic formulation in India. It consists of three well known plants, viz., Piper longum (PL), Piper nigrum (PN) and Zingiber officinale (ZO) in equal ratio. Trikatu has been prescribed for cough, cold, fever, asthma, respiratory problems and improvement of digestive disorders. The aim of the present study was to investigate the effect of individual ingredients of trikatu namely PL, PN, and ZO and formulations [Marketed formulation (MF) and laboratory formulation (LF)] on drug metabolizing enzymes (CYP3A4 and CYP2D6), to assess its herb–drug interaction potential through cytochrome P450 inhibition assays. Further this work was aimed to develop an RP-HPLC method for the identification and quantification of piperine and 6-gingerol in the crude drug trikatu.

Materials and methods

Enzyme inhibition effect of LF, MF, PL, PN and ZO was explored through CYP450–CO complex assay using rat liver microsomes (RLM) and a fluorescence screening method using individual isoenzymes (CYP3A4 and CYP2D6). The RP-HPLC method was developed for the identification and quantification of piperine and 6-gingerol in LF, MF and individual plant materials at the concentration of 1 mg/mL.

Results

RP-HPLC analysis confirmed the presence of piperine and 6-gingerol in LF and MF [Piperine: 7.89±2.12% (w/w) (MF), 6.70±2.13% (w/w) (LF)]; [6-gingerol: 5.3±1.21% (w/w) (MF), 4.95±2.34% (w/w) (LF)]. Inhibitory potential of MF and LF in CYP450–CO complex assay was found to be 37.54±3.12% (MF) and 35.12±2.31% (LF) and against CYP2D6 and CYP3A4 was estimated to be IC₅₀ 251.30±3.98 and 245.23±1.92 渭g/mL and IC₅₀ 225.50±1.02 and 223.254±0.92 渭g/mL respectively.

Conclusions

Different concentrations of the trikatu formulation and its individual components showed significantly (p<0.001) less inhibitory activity on individual isoenzymes as compared to the positive control. The crude drug exhibited inhibitory potential against the CYP450 enzymes in a concentration dependent manner. Outcome of the present study demonstrated that trikatu has less interaction potential with drug metabolizing enzymes.